Royalty Pharma plc (NASDAQ:RPRX) Q1 2023 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX) Q1 2023 Earnings Call Transcript May 9, 2023
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call. I would now like to turn the call over to George Grofik, SVP, Head of Investor Relations and Communications. Please go ahead, sir.
George Grofik: Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma’s first quarter 2023 results. You can find the press release with our earnings results and slides of this call on the Investors page of our website at royaltypharma.com. Moving to Slide 3. I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. I refer you to our 10-K on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma, and we assume no obligation to update any such forward-looking statements.
Non-GAAP financial measures will be used to help you understand our financial performance. The GAAP to non-GAAP reconciliations are provided in the earnings press release available on our website. And with that, please advance to Slide 4. Our speakers on the call today are Pablo Legorreta, Founder and Chief Executive Officer; Marshall Urist, EVP, Head of Research and Investments; and Terry Coyne, EVP, Chief Financial Officer. Pablo will discuss the key highlights Marsh will then provide a portfolio update, after which Terry will review the financials. Following concluding remarks from Pablo, we will hold a Q&A session when we will be joined by Chris Hite, EVP, Vice Chairman. With that, I’d like to turn the call over to Pablo.
Pablo Legorreta: Thank you, George, and welcome to everyone on the call. I am delighted to report a strong start to 2023 as we deliver on our strategy as a leading funder of Innovation and Life Sciences. Slide 6 summarizes our financial and portfolio achievements in the first quarter, which again highlights our strong momentum and the power of our business model. First, we delivered strong performance. Adjusted cash receipts, our top-line grew by 11%. Adjusted EBITDA also by 11%, and adjusted cash flow grew by 49%. All the strong metrics were prior to the Biohaven related payments, which I will discuss on the next slide. Second, on capital allocation, we announced royalty position of up to $1.6 billion including $600 million in upfront payments and a multiyear share repurchase program of up to $1 billion.
I also personally intend to acquire up to an additional $50 million of Royalty Pharma stock given the compelling value, I believe the share represents. Third, we strengthened our royalty portfolio. We added three new therapies, including the SMA blockbusters Spinraza, and the exciting development stage therapies, pelacarsen and KarXT, both of which are potential future blockbusters on consensus estimates. Additionally, three medicines in our portfolio were approved by the FDA, and Xtandi had a positive Phase 3 readout for a potential label expansion with the EMBARK study. Fourth, we are reaffirming our increased full year guidance for adjusted cash receipts. Our guidance reflects expected underlying growth from our portfolio of between 4% and 9% prior to the Biohaven related payments.
Consistent with our standard practice, our guidance is based on our current portfolio and does not include the benefit of any future acquisitions this year. On Slide 7, you can see our financials in more detail. We delivered 11% growth in our top-line prior to the Biohaven related payments and 87% growth if we increase includes the payments. As a reminder, the major nonrecurring items here are the $475 million milestone we received from Pfizer in March 2023, following the approval of Zavzpret for migraine, as well as the $13 million fixed Biohaven related payments were received in the same period a year ago. Foreign exchange continued to represent a headwind impacting our top-line by around minus 3% to minus 4% in the quarter. Consistent with our top-line, we grew our adjusted EBITDA by 11% in the quarter prior to the Biohaven related payments and 88%, including this payment.
Adjusted EBITDA is an important non-GAAP measure for us, which is arrived at by divesting payments for operating and professional costs from our top-line. Lastly, our adjusted cash flow, our bottom line grew by 49% in the quarter prior to the Biohaven related payments and 165%, including this payment. The substantial increase in the quarter also reflected the $100 million upfront and milestone development stage payments to Cytokinetics in the prior year. Slide 8 shows our impressive track record of strong top-line growth since our IPO in June of 2020, including our double-digit growth in the first quarter. This reflects our ability to execute successfully and consistently against our strategy. Slide 9 provides a deeper dive into our top-line performance in the quarter to show the various moving parts.
The strong performance of our base business and our acquisition of the Trelegy royalties allow us to deliver 11% top-line growth before taking into account the impact of the Biohaven related payments. Royalty expirations and tranching together represented a combined headwind to growth in the 7% to 8% range. The strong underlying dynamics in the quarter once again underscore the unique power of our business model to replenish our portfolio and to drive compounding growth. With that, I will hand it over to Marshall to update you on our portfolio.
Marshall Urist: Thanks, Pablo. On the next few slides, I want to discuss our recent transactions in schizophrenia and also to provide a broader perspective on our approach to portfolio strategy. Last month, we were delighted to announce the acquisition of PureTech’s royalty on Karuna’s KarXT. This is a novel oral muscarinic agonist with two positive Phase 3 trials in schizophrenia. KarXT is also in development for the treatment of psychosis in Alzheimer’s disease. In return for an upfront payment of $100 million and $400 million in potential regulatory and sales milestones we will receive a 3% royalty on annual sales of KarXT up to $2 billion and approximately 1% above this threshold to provide some context for modeling the potential outflows for this transaction.
The vast majority of the milestones require very strong commercial performance. Our excitement about this development stage medicine is driven by the results of the clinical program, including two Phase 3 studies, EMERGENT-2 and EMERGENT-3 and the significant need for new novel therapies in schizophrenia. Not only did the trials demonstrate early and sustained reductions in the positive and negative symptoms of schizophrenia, but importantly, – the tolerability profile was very encouraging, especially regarding some of those common adverse events typically associated with current medications, including weight gain, somnolence and extrapyramidal symptoms. Based on these strong results, Karuna plan to submit a new drug application to the FDA in the third quarter of this year.
The street has certainly recognized the exciting profile of this compound with consensus sales projections rising to $5 billion by 2030. Slide 12 expands on the significant unmet need for new treatments in schizophrenia. On the left hand side, you can see that close to a third of patients do not respond to current therapy and only about half have a partial improvement or suffer unacceptable side effects. When taken together with the particular challenges of this disease, this results in approximately three quarters of patients discontinuing treatment within 18 months, which underscores the need for new treatment approaches. This is why we are so excited to have invested in two novel mechanisms of action through KarXT and MK-8189. Each potentially offers a differentiated clinical profile from current medications most notably on tolerability.
KarXT, as I just highlighted, has already reported positive Phase 3 results and will be marketed by Karuna subject to FDA approval, and MK-8189 is a PDE10A inhibitor in Phase 2b where a potential royalty arises from a unique collaboration between Royalty Pharma and Merck. Taken together, this is another illustration of our unique ability to invest in multiple therapies in the same category where we see the potential for innovation to transform patient lives. Slide 13 returns to a concept that we showed at our Investor Day last year on selected investment themes of interest. Our investments in the schizophrenia category are consistent with two of these themes. The first is to explore the potential of under-innovated large markets where there is arguably been less industry-focused given the shift towards specialty markets with smaller patient populations and higher price points.
Schizophrenia is a great example of a large under-innovated market, and we believe that KarXT and MK-8189 could bring important benefits to patients in this complex and difficult-to-treat population. In addition, we believe brain disease has tremendous scope for innovation with limited effective treatment options in many cases. Schizophrenia sits squarely in this heterogeneous category. Lastly, on Slide 14, I want to provide a long-term perspective on our balanced royalty acquisition strategy. This data shows how we have deployed our capital since 2012 between approved and development stage opportunities. On the left-hand side, you see that since we started investing in development stage therapies in 2012 of the approximately $21 billion in capital deployed, the majority of the investments have been in approved products.
Photo by freestocks on Unsplash
On the right-hand side, you can see that the percentage deployed annually has exhibited significant variability on an annual basis, in part reflecting the opportunistic nature of our business, but in aggregate has also been skewed towards approved products on average at 59% of total capital. So while we do not have target levels of investment between approved and development stage, our therapeutic area agnostic approach to investing and position us the partner of choice in the royalty funding market – has allowed us to fund innovation in a balanced way while maintaining strong returns and long-term growth. With that, I’ll hand over to Terry.
Terry Coyne: Thanks, Marshall. Let’s move to Slide 16. Total royalty receipts grew 72% in the first quarter versus the year ago period. Excluding the Biohaven related payments in each quarter, royalty receipts grew approximately 8%. The magnitude of growth reflects the $475 million Zavzpret milestone payment, together with strong contributions from the cystic fibrosis franchise, Tremfya and the Trelegy royalty, which we acquired last July. We also saw growing royalty contributions from Evrysdi and Cabometyx and from other medicines not shown on this slide, particularly Trodelvy and Orladeyo. Lastly, we received a $35 million payment related to AstraZeneca’s Airsupra. These positive factors were partially offset by the loss of the DPP-IV royalties by weakness in Imbruvica and to a lesser extent, Tysabri and by the adverse FX impact.
Slide 17 shows how our efficient business model generates substantial cash flow to be redeployed. As you’re aware, adjusted cash receipts is a key non-GAAP metric for us, which we arrived at after deducting distributions to non-controlling interests. This amounted to $1.1 billion in the quarter or growth of 87% compared with last year’s first quarter. As Pablo noted earlier, prior to the impact of Biohaven related payments, growth would have been 11% in the quarter. As we move down the column, operating and professional costs were approximately 8% of adjusted cash receipts in the quarter. As a consequence, we reported 88% growth in adjusted EBITDA in the quarter, relatively consistent with our top-line growth. When we think of the cash generated by the business to be redeployed into new value-enhancing royalties, we look to adjusted EBITDA less net interest paid.
Net interest paid in the quarter of $67 million reflected the semiannual timing of the payments on our $7.3 billion of unsecured notes, which occur in the first and third quarters. This figure included $16 million we received in interest given the strong cash position on our balance sheet, which benefited from higher interest rates. We did not have upfront and milestone payments for development stage funding in the quarter, whereas the prior year period included a $100 million payment related to Cytokinetics. As a consequence, adjusted cash flow, our bottom line grew significantly faster than adjusted cash receipts and adjusted EBITDA and amounted to $973 million or $1.60 per share for the quarter. This resulted in an adjusted cash flow margin of 86%, which once again highlights the efficiency of our business model.
Let’s move now to Slide 18 and our financial position. We continue to maintain significant financial firepower for future royalty acquisitions. In the first quarter, we deployed a little over $600 million of capital on royalty acquisitions as well as around $120 million on dividends. This was more than offset by our strong cash flow generation over the quarter, so that our cash and marketable securities increased to $2 billion at the end of March. Our leverage at the end of the quarter stood at a comfortable 2.3 times total debt-to-EBITDA and 1.7 times net debt-to-EBITDA. As I have previously highlighted, the fixed rate average coupon on our debt is slightly above 2%, which compares to our target returns on royalty acquisitions in the high single-digit to teens percentage range.
In addition, around 60% of our debt matures in 2030 or beyond. Taken together, we continue to believe that our cost of capital and debt maturity profile represent a durable competitive advantage for our business. Based on our financial strength and efficient business model, we remain confident in our ability to execute on our business plan and create value for shareholders. On Slide 19, I want to remind you of our capital allocation strategy and how we expect this to drive shareholder value creation. At our Investor Day last May, we outlined that over a five-year period through a combination of cash generation and our debt capacity we expect to have access to around $20 billion of capital. As you can see on this slide, the majority of our capital will be deployed on value-enhancing royalty acquisitions – with a target of $10 billion to $12 billion invested over the period.
In fact, as many of you are aware, we are running a bit ahead of this schedule, having announced transactions of up to $5 billion in 2022. Furthermore, given the tailwinds in our industry and our powerful market positions, our transaction pipeline continues to remain robust and highly active. We aim to balance this primary focus on royalty acquisitions with returning to capital to shareholders through a combination of dividends and when appropriate, share repurchases. Recently, the Board authorized a multiyear share buyback program of up to $1 billion, which is a reflection of the compelling value we see in our share price and our focus on efficient capital allocation to drive shareholder returns. By executing against this capital allocation strategy, we are confident we will continue to deliver on our mission of accelerating innovation in life sciences while generating strong returns and creating significant shareholder value.
Slide 20 provides our full year 2023 financial guidance. We expect adjusted cash receipts to be in the range of $2.85 billion to $2.95 billion, consistent with the raised outlook we provided in March following receipt of the Zavzpret milestone payment. Importantly, and consistent with our standard practice, this guidance is based on our portfolio as of today and does not take into account the benefit of any future royalty acquisitions. Turning to our operating costs. We expect payments for operating and professional costs to be approximately 8% to 9% of adjusted cash receipts in 2023, in line with previous guidance. We continue to believe that the degree of margin protection provided by our unique business model is impressive in today’s inflationary environment.
Similarly, interest paid for full year 2023 is still expected to be around $170 million and to follow the established quarterly pattern with de minimis amounts payable in Q2 and Q4. This does not take into account interest received on our cash balance, which was $16 million in the first quarter. You should also note that we expect to make a $50 million milestone payment to Cytokinetics in the second half of 2023 based on the company’s guidance of initiating their pivotal trial of Aficamten in non-obstructive hypertrophic cardiomyopathy. This $50 million expense will be recorded as a development stage funding payment and thus reduce adjusted cash flow this year. Lastly, as many of you are aware, the royalties we receive lagged sales by one quarter, live product sales by one quarter.
Additionally, several of our largest royalties are tiered, which typically reset at the beginning of the year and have the potential to increase throughout the year. Therefore, there is some seasonality to our business, and the second quarter tends to be lower than other quarters in the year, and the first quarter tends to be higher. Accordingly, we would expect adjusted cash receipts in the second quarter to be slightly higher compared with the same quarter in 2022. My final slide drills down further on our adjusted cash receipts guidance. The graphic is illustrative, but sets out the various pushes and pulls behind our outlook for 2023. Starting with the left hand side, we have faced a high base of comparison due to the $509 million of Biohaven related payment, which we received in 2022.
Adjusting for these payments brings the underlying base for 2022 adjusted cash receipts to $2.28 billion. On the right side, if we start from the adjusted cash receipt base prior to Biohaven, we expect underlying growth of 4% to 9% this year, which we anticipate to be driven by the CF franchise, Tremfya and a full year of Trelegy royalties. Partially offset by the losses of exclusivity on the DPP-IV and Imbruvica weakness, which we believe we have conservatively reflected in our guidance. We also expect a modest contribution from three quarters of Spinraza royalties. As mentioned earlier, this growth does not include the benefit of any future acquisitions. Using today’s U.S. dollar exchange rates, FX is expected to represent a relatively modest headwind of minus 1% to minus 2%.
Putting this all together, including the $475 million payment, milestone payment on Zavzpret, we are reaffirming our increased top-line guidance of $2.85 billion to $2.95 billion. With that, I would like to hand the call back to Pablo for his closing comments.
Pablo Legorreta: Thanks, Terry. Let me close by saying how pleased I am with our excellent start to 2023. This sets us up well to deliver on our guidance for the full year and to continue to execute strongly against our strategy. To finish on Slide 23, I would like to highlight why Royalty Pharma’s business model offers a unique way to invest in biopharma. Starting with growth. As we announced at our Investor Day, we expect to deliver a top-line CAGR of more than 10% or more over this decade, which compares with consensus expectations of 4% for large biopharma. Despite being a relatively small company in terms of head count, we offer the benefits of scale with exposure to 15 blockbuster medicines as compared with an average of nine for the large biopharma companies.
We have a similar low cost of capital for our development stage investments tend to be lower risk as we generally do not invest in therapies before clinical proof-of-concept, thereby avoiding the high failure rate of preclinical and early-stage clinical compounds. We have consistently delivered an attractive low double-digit rate of return on our investments and our – and while we are unable to provide a precise comparison with large biopharma, as you know, the R&D productivity of the industry and returns on acquisitions are open for debate. We also offer a yield around 2%. And last but not least, our management team is fully aligned with shareholder interest with high ownership of the company, which is significantly higher than the management ownership in large biopharma.
The ownership for named executive officers of Royalty Pharma is 16%, which compares to less than 1% for our large cap biopharma peers. However, when we consider all employees and the Board, ownership of areas department is even higher at around 32%. Taken together, I truly believe Royalty Pharma offers a unique, powerful business model with a very attractive growth and return profile when compared to the biopharma industry. With that, we would be happy to take your questions.
George Grofik: We’ll now open up the call to your questions. Operator, please take the first question.
See also U.K. Dividend Champions List: 2023 Rankings by Yield and 35 Best Thriller Movies on Netflix.
To continue reading the Q&A session, please click here.
